Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
6(100.0%)
6Total
Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05463224Phase 2Active Not Recruiting

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

Role: lead

NCT07432984Phase 2Not Yet Recruiting

Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC

Role: lead

NCT06830694Phase 2Recruiting

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Role: lead

NCT03578185Recruiting

Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy

Role: lead

NCT04361825Phase 2Completed

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

Role: lead

NCT04939662Phase 2Completed

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

Role: lead

NCT04525391Phase 2Terminated

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

Role: lead

All 7 trials loaded